Efficacy and Safety of Pyronaridine-artesunate for the Treatment in Uncomplicated Falciparum Malaria

Inclusion Criteria: * Adults and children ≥ 20 kg * Symptomatic of malaria infection, i.e. history of fever within 24 hours and/or presence of fever \>37.5°c. * Microscopic confirmation of asexual stages of P. falciparum (P. falciparum and mixed infection in Pailin only) * Capability of taking an oral medication * Written informed consent given to participate in the trial * Willingness and ability to adhere to follow-up visit schedule Exclusion Criteria: * Pregnancy or lactation (urine test for β HCG to be performed on any woman of child bearing age, that is 18 to 45 y/o) * Female aged 12-18y * Parasitemia \> 150 000/µL). * Signs or symptoms indicative of severe malaria: * Impaired consciousness (Blantyre Coma Score \<5) * Severe anaemia (Hct\<15%) * Bleeding disorder -evidenced by epistaxis, bleeding gums, frank haematuria, bleeding from venepuncture sites * Respiratory distress * Severe jaundice * Known hypersensitivity to artemisinins - defined as history of erythroderma/other severe cutaneous reaction, angioedema or to pyronaridine * History of splenectomy * Known history or evidence of clinically significant disorders, such as: * Known active Hepatitis A, e.g. by detection of anti HAV-IgM. * Known hepatitis B surface antigen (HBsAg) carrier. * Known hepatitis C antibody (HCV Ab). * Liver function tests (AST/ALT levels) more than 2.5 times the upper limit of normal range.